Genome sequencing has largely failed to deliver promised medical treatments for common complex diseases: a UCL team published in the BMJ in October last year showed that polygenic scores, built using the same techniques as a clinical drug trial, simply do not work for cardiovascular disease and cancer — which together account for 60% of fatalities — though monogenic (rare single-gene) diseases remain a valid target for genetic cures.